Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy - PubMed (original) (raw)
. 2021 Oct 14;7(1):36-45.
doi: 10.1016/j.ekir.2021.10.008. eCollection 2022 Jan.
Gerasimos Filippatos 3, Rajiv Agarwal 4, Stefan D Anker 5, Bertram Pitt 6, Luis M Ruilope 7 8 9, Juliana C N Chan 10 11 12, Adriaan Kooy 13 14 15, Kieran McCafferty 16, Guntram Schernthaner 17 18, Christoph Wanner 19, Amer Joseph 20, Markus F Scheerer 21, Charlie Scott 22, George L Bakris 23; FIDELIO-DKD Investigators
Affiliations
- PMID: 35005312
- PMCID: PMC8720648
- DOI: 10.1016/j.ekir.2021.10.008
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing et al. Kidney Int Rep. 2021.
Abstract
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone.
Methods: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m2 receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993).
Results: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66-0.71) and 0.75 (95% CI -= 0.62-0.90), respectively (P interaction = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P interaction = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without).
Conclusion: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i.
Keywords: albuminuria; chronic kidney disease; finerenone; sodium-glucose cotransporter-2 inhibitors; type 2 diabetes.
© 2021 International Society of Nephrology. Published by Elsevier Inc.
Figures
Graphical abstract
Figure 1
Analysis of primary and secondary composite outcomes by baseline SGLT-2i use. CV, cardiovascular; SGLT-2i, sodium-glucose cotransporter-2 inhibitor.
Figure 2
Effect on albuminuria over time by baseline SGLT-2i use. Mixed-model analysis of UACR levels in patients who were (a) with or (b) without an SGLT-2i at baseline. Analysis included the following covariates: treatment group, stratification factors (region, albuminuria category at screening, eGFR category at screening), time, treatment over time, log-transformed baseline value nested within type of albuminuria at screening, and log-transformed baseline value over time. The change in UACR at month 4 was consistent irrespective of treatment with an SGLT-2i at baseline (_P_interaction = 0.31). eGFR, estimated glomerular filtration rate; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; LS, least-squares; UACR, urine albumin-to-creatinine ratio.
Similar articles
- Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Agarwal R, et al. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336. Nephrol Dial Transplant. 2022. PMID: 34850173 Free PMC article. Clinical Trial. - Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R. Filippatos G, et al. JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12. JACC Heart Fail. 2022. PMID: 36328655 Clinical Trial. - Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, González F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Rosas SE, et al. Kidney Med. 2023 Aug 1;5(10):100704. doi: 10.1016/j.xkme.2023.100704. eCollection 2023 Oct. Kidney Med. 2023. PMID: 37745646 Free PMC article. - Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB, Pergola P. Wish JB, et al. Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec. Mayo Clin Proc Innov Qual Outcomes. 2022. PMID: 36277502 Free PMC article. Review. - Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J, Palmer BF. Morales J, et al. Postgrad Med. 2024 Mar;136(2):111-119. doi: 10.1080/00325481.2024.2316572. Epub 2024 Feb 16. Postgrad Med. 2024. PMID: 38344772 Review.
Cited by
- A new perspective on proteinuria and drug therapy for diabetic kidney disease.
Zhang R, Wang Q, Li Y, Li Q, Zhou X, Chen X, Dong Z. Zhang R, et al. Front Pharmacol. 2024 Jul 31;15:1349022. doi: 10.3389/fphar.2024.1349022. eCollection 2024. Front Pharmacol. 2024. PMID: 39144629 Free PMC article. Review. - Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.
Khan MS, Lea JP. Khan MS, et al. BMC Nephrol. 2024 Aug 1;25(1):248. doi: 10.1186/s12882-024-03652-5. BMC Nephrol. 2024. PMID: 39090593 Free PMC article. Review. - Management of chronic kidney disease: The current novel and forgotten therapies.
Pethő ÁG, Tapolyai M, Csongrádi É, Orosz P. Pethő ÁG, et al. J Clin Transl Endocrinol. 2024 May 22;36:100354. doi: 10.1016/j.jcte.2024.100354. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38828402 Free PMC article. Review. - Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities.
Sarzani R, Landolfo M, Di Pentima C, Ortensi B, Falcioni P, Sabbatini L, Massacesi A, Rampino I, Spannella F, Giulietti F. Sarzani R, et al. Front Med (Lausanne). 2024 Apr 8;11:1365183. doi: 10.3389/fmed.2024.1365183. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38654832 Free PMC article. Review. - Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
Wang N, Zhang C. Wang N, et al. Int J Mol Sci. 2024 Mar 7;25(6):3086. doi: 10.3390/ijms25063086. Int J Mol Sci. 2024. PMID: 38542060 Free PMC article. Review.
References
- Incidence, prevalence, patient characteristics, and treatment modalities United States Renal Data System. Published 2020. Accessed 13 April 2021. https://adr.usrds.org/2020/end-stage-renal-disease/1-incidence-prevalenc...
- Buse J.B., Wexler D.J., Tsapas A., et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018 A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetologia. 2020;63:1667] Diabetologia. 2020;63:221–228. doi: 10.1007/s00125-019-05039-w. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous